What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19

por Osborne, Vicki, Shakir, Saad A. W.
Publicado 2021

The Role of the Contextual Cohort to Resolve Some Challenges and Limitations of Comparisons in Pharmacoepidemiology

por Osborne, Vicki, Lane, Samantha, Shakir, Saad A. W.
Publicado 2021

Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?

por Dhanda, Sandeep, Osborne, Vicki, Lynn, Elizabeth, Shakir, Saad
Publicado 2022

Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England

por Osborne, Vicki, Davies, Miranda, Evans, Alison, Shakir, Saad A. W.
Publicado 2020

Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Result...

por Evans, Alison, Davies, Miranda, Osborne, Vicki, Roy, Debabrata, Shakir, Saad
Publicado 2020

Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an...

por Evans, Alison, Davies, Miranda, Osborne, Vicki, Roy, Debabrata, Shakir, Saad
Publicado 2020

Indicators of Drug-Seeking Aberrant Behaviours: The Feasibility of Use in Observational Post-Marketing Cohort Studies for Risk Management

por Layton, Deborah, Osborne, Vicki, Al-Shukri, Mohammad, Shakir, Saad A. W.
Publicado 2014

Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management

por Osborne, Vicki, Davies, Miranda, Roy, Debabrata, Tescione, Francesco, Shakir, Saad A W
Publicado 2020

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England

por McNaughton, Rhian, Lynn, Elizabeth, Osborne, Vicki, Coughtrie, Abigail, Layton, Deborah, Shakir, Saad
Publicado 2016

Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment

por Davies, Miranda, Osborne, Vicki, Lane, Samantha, Roy, Debabrata, Dhanda, Sandeep, Evans, Alison, Shakir, Saad
Publicado 2020

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment

por Osborne, Vicki, Davies, Miranda, Lane, Samantha, Evans, Alison, Denyer, Jacqueline, Dhanda, Sandeep, Roy, Debabrata, Shakir, Saad
Publicado 2020

A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events

por Dhanda, Sandeep, Evans, Alison, Roy, Debabrata, Osborne, Vicki, Townsley, Adam, Coutinho, Graça, Kulasekaran, Anuradha, Shakir, Saad
Publicado 2021